PRGO earnings
Perrigo Company plc (PRGO) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Perrigo Reports First Quarter 2026 Financial Results From Continuing OperationsMitigating category headwinds with market share gains through implementation of Three‑S plan.Specialty Care segment achieved net sales and segment operating income growth, led by continued momentum in Compeed®, Opill®, and ellaOne® brands.Completed divestiture of Dermacosmetics business after quarter end; upfront proceeds of approximately €306 million will support debt reduction.Maintained full‑year 2026 outlook with continued expectation for second half improvement.DUBLIN, May 6, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced financial results from continuing operations for the first quart
- Perrigo to Release First Quarter 2026 Financial Results on May 6, 2026DUBLIN, April 22, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of consumer health products, today announced that it plans to issue its first quarter 2026 financial results on Wednesday, May 6, 2026, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 82404. A taped replay of the call will be available b
- Perrigo to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026DUBLIN, Feb. 13, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of consumer health products, today announced that it plans to issue its fourth quarter and fiscal year 2025 financial results on Thursday, February 26th, 2026, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 52719.
- Perrigo Reports Third Quarter 2025 Financial Results From Continuing OperationsAmid Soft Market Consumption Trends, Achieved Q3 2025 Dollar, Unit and Volume Share(1) Gains in 5 of 7 Over-The-Counter ("OTC") Store Brand Categories and Dollar Share Gains in Key Brands Despite Marketplace Challenges, Delivered Meaningful YTD 2025 EPS Growth(2) with Gross and Operating Margin Expansion Initiates Strategic Review of Infant Formula Business (Announced in Separate Press Release); Continues Strategic Review of Oral Care Business; On-Track to Close Previously Announced Sale of Dermacosmetics Business in Q1'26 Updates Full Year 2025 Outlook Due Primarily to Infant Formula Industry Dynamics and Soft OTC Market Consumption Trends DUBLIN, Nov. 5, 2025 /PRNewswire/ --
- Perrigo to Release Third Quarter 2025 Financial Results on November 5, 2025DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2025 financial results on Wednesday, November 5th, 2025, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 03742. A taped repla
- Perrigo Reports Second Quarter 2025 Financial Results From Continuing OperationsCompany Advanced its 'Three-S' Plan (Stabilize, Streamline, and Strengthen) with Recently Announced Agreement to Sell Dermacosmetics Business, Scaling of Global Operating Growth Model, and Upgraded Brand Building Capabilities that are Delivering Results Solid Execution Amid Challenging Market Consumption Trends Reaffirms Full Year 2025 Adj. EPS Target Range of $2.90 - $3.10 DUBLIN, Aug. 6, 2025 /PRNewswire/ -- Second Quarter 2025 YoY Highlights: Net Sales: $1.06 billion, down 0.9% year-over-year. Favorable currency translation (+1.7%) was more than offset by the impact of di
- Perrigo to Release Second Quarter 2025 Financial Results on August 6, 2025DUBLIN, July 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2025 financial results on Wednesday, August 6th, 2025, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 45051. A taped replay
- Perrigo Reports First Quarter 2025 Financial Results From Continuing OperationsAdvancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN, May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested
- Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025DUBLIN, April 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2025 financial results on Wednesday, May 7th, 2025, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 04449. A taped replay o
- Perrigo to Release Fourth Quarter and Fiscal Year 2024 Financial Results on February 27, 2025, Host Virtual Investor Day on February 28, 2025DUBLIN, Ireland, Jan. 31, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 2024 financial results after the U.S. equity markets close on February 27, 2025. The Company plans to host its Virtual Investor Day on February 28, 2025, beginning at 8:00 AM EST. Interested parties are invited to access the Virtual Investor Day event at Perrigo-Investor-Day-2025.open-exchange.net/welcome and are encouraged to register in advance. About Perrigo Perrigo Comp
- Perrigo Reports Third Quarter 2024 Financial Results From Continuing OperationsCompany Delivered Solid Third Quarter Financial Results, Including Meaningful Operating Income Growth and Margin Expansion Infant Formula Business Recovery Making Significant Progress, Including Perrigo Produced and Store Brand Infant Formula Market Share Gains1; Third Quarter 2024 Infant formula Net Sales Growth of +3% Compared to the Prior Year Quarter, +58% Sequentially Reaffirms Fiscal 2024 Adjusted EPS Outlook DUBLIN, Nov. 6, 2024 /PRNewswire/ -- Third Quarter 2024 Highlights: Net sales of $1.1 billion declined 3.2% versus the prior year quarter. Organic2 net sales decrea
- Perrigo to Release Third Quarter 2024 Financial Results on November 6, 2024DUBLIN, Oct. 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2024 financial results on Wednesday, November 6, 2024, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 96443. A taped replay
- Perrigo Reports Second Quarter 2024 Financial Results From Continuing OperationsDelivered Adjusted Diluted Earnings Per Share Results as Expected; Reaffirm Fiscal 2024 Adjusted Diluted EPS Outlook Progressing One Perrigo Blueprint: On Target to Deliver Project Energize Goals; Enhancing Capabilities; Completed Divestment of HRA Pharma Rare Diseases Business on July 10, 2024 DUBLIN, Aug. 2, 2024 /PRNewswire/ -- Second Quarter 2024 Highlights: Net sales of $1.1 billion declined 10.7% versus the prior year quarter. Organic1 net sales decreased 9.1%, due primarily to -6.8 percentage points from lower net sales of infant formula driven by actions to augment and
- Perrigo to Release Second Quarter 2024 Financial Results on August 2, 2024DUBLIN, July 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2024 financial results on Friday, August 2, 2024, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, International 416-764-8650, and reference ID # 294776. A taped replay of
- Perrigo Reports First Quarter 2024 Financial Results From Continuing OperationsDelivered Adjusted Diluted Earnings Per Share Results Above Projection, Due Primarily to Timing of Infant Formula Shipments; Reaffirm 2024 Financial Outlook Advanced Augmenting and Strengthening of Infant Formula Facilities, Recovery of Manufacturing Volumes Underway Progressed Blueprint to Build One Perrigo; On Target to Deliver Project Energize Goals; Announced Today in a Separate Press Release the Executive Transition for the Consumer Self-Care International Business Recently Announced Plan to Divest HRA Rare Diseases Business; Expects to Redeploy Proceeds for Debt Paydown DUBLIN, May 7, 2024 /PRNewswire/ --
- Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024DUBLIN, April 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7th, 2024, and host a conference call beginning at 8:30 A.M. (EDT). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, International 416-764-8650, and reference ID # 910565. A taped replay of
- Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency ProgramNet Sales from Continuing Operations Were a Fourth Quarter and Fiscal Year Record Delivered Fiscal Year 2023 Double-Digit Improvement in Gross Profit, Operating Income and EPS, Year-Over-Year Achieved Sixth Consecutive Quarter of Year-Over-Year Gross Margin Expansion Launching 'Project Energize' Investment and Efficiency Program to Drive the Company's One Perrigo Sustainable, Value Accretive Growth Strategy DUBLIN, Feb. 27, 2024 /PRNewswire/ -- Fourth Quarter 2023 Highlights: Fourth quarter net sales of $1.2 billion grew 0.1% versus the prior year quarter. Organic1 net sale
- Perrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 27, 2024DUBLIN, Feb. 13, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 2023 financial results on Tuesday, February 27th, 2024 and will host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, International 617-892-4906, and reference ID #
- Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results From Continuing OperationsAchieved Year-Over-Year and Sequential Gross and Operating Margin Expansion Delivered Strong Operating Income and EPS Growth Reaffirming 2023 Outlook DUBLIN, Aug. 8, 2023 /PRNewswire/ -- Second Quarter 2023 Highlights: Second quarter net sales of $1.2 billion grew 6.4%, or 6.6% on a constant currency1 basis, versus the prior year quarter. Organic2 net sales grew 0.8%, including -2.7 percentage points from purposeful SKU prioritization actions to enhance margins as part of the Company's Supply Chain Reinvention Program.Consumer Self-Care Americas ("CSCA") net sales grew 3.1%,
- Perrigo Reports First Quarter Fiscal Year 2023 Financial Results From Continuing OperationsDUBLIN, May 9, 2023 /PRNewswire/ -- First Quarter 2023 Highlights: First quarter net sales grew 10.0% versus the prior year quarter to $1.2 billion. Constant currency net sales(1) increased 13.0% and organic(2) net sales grew 6.4% compared to the prior year quarter.Consumer Self-Care Americas ("CSCA") and Consumer Self-Care International ("CSCI") segments delivered strong net sales growth of 7.6% and 14.7%, respectively, compared to the prior year quarter. CSCI achieved record net sales in the quarter, highlighted by constant currency net sales growth of 23.6% compared to the
- Perrigo to Release First Quarter 2023 Financial Results on May 9, 2023DUBLIN, April 25, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2023 results on Tuesday, May 9, 2023. The Company will also host a conference call beginning at 8:30 A.M. (EST). The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-317-6003, International 412-317-6061, and reference ID # 1820838. A taped replay of th
- Perrigo to Release Fourth Quarter and Fiscal Year 2022 Financial Results on February 27, 2023, Conduct Virtual Investor Day on February 28, 2023DUBLIN, Feb. 14, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 2022 financial results after the U.S. equity markets close on February 27, 2023. As a reminder, the Company plans to host its Virtual Investor Day on February 28, 2023, beginning at 8:00 AM EST. All interested parties are invited to access the event at https://perrigo-investor-day-2023.open-exchange.net and are encouraged to register in advance. About Perrigo Perrigo Company plc (NYS
- Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing OperationsDUBLIN, Nov. 8, 2022 /PRNewswire/ -- Highlights: Perrigo achieved third quarter net sales of $1.1 billion, an increase of 5.5%, or 12.3% excluding the impact of currency translation, versus the prior year quarter. Year-to-date net sales increased 8.7%, or 14.0% excluding the impact of currency translation, versus the prior year period. Organic(1) net sales increased 7.7% in the third quarter and 11.4% year-to-date compared to the prior year periods. Third quarter reported gross margin was 33.0%. Third quarter adjusted gross margin was
- Perrigo to Release Third Quarter 2022 Financial Results on November 8, 2022DUBLIN, Oct. 25, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022. The Company will also host a conference call beginning at 8:30 A.M. (EST). The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-317-6003, International 412-317-6061, and reference ID # 8518983. A taped
- PERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONSDUBLIN, Aug. 9, 2022 /PRNewswire/ -- Second Quarter 2022 Highlights:Perrigo achieved second quarter net sales of $1.1 billion, an increase of 14.3%, or 20.2% excluding the impact of currency translation, versus the prior year quarter. Organic(1) net sales increased 17.2%, driven by continued strong global demand for the Company's consumer self-care products.Perrigo second quarter reported gross margin was 33.2%. Second quarter adjusted gross margin was 36.5%, an increase of 310 basis points sequentially compared to the first quarter 2022, while down 190 basis points compared t
- PERRIGO TO RELEASE SECOND QUARTER 2022 FINANCIAL RESULTS ON AUGUST 9, 2022DUBLIN , July 27, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022. The Company will also host a conference call beginning at 8:30 A.M. (EDT). The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-317-6003, International 412-317-6061, and reference ID # 4031017. A taped
- PERRIGO REPORTS FIRST QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS, RAISES GUIDANCEDUBLIN, May 11, 2022 /PRNewswire/ -- Highlights: Perrigo achieved first quarter net sales of $1.1 billion, an increase of 6.4% versus the prior year quarter. Organic(1) net sales increased 9.7%, led by continued strong consumer demand, particularly for cough/cold products globally and infant formula in the U.S. Reported loss per diluted share for the first quarter of 2022 was $0.01, as compared to earnings per diluted share ("EPS") of $0.02 in the prior year quarter. Adjusted diluted EPS for the first quarter of 2022 was $0.33 per diluted share, as compared to $0.50 per dilut
- PERRIGO TO RELEASE FIRST QUARTER 2022 FINANCIAL RESULTS ON MAY 11, 2022DUBLIN, April 27, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022. The Company will also host a conference call beginning at 8:30 A.M. (EDT). The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-317-6003, International 412-317-6061, and reference ID # 7280612. A taped r
- PERRIGO REPORTS FOURTH QUARTER & FISCAL YEAR 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONSDUBLIN, March 1, 2022 /PRNewswire/ -- Highlights: Fourth quarter net sales grew 4.9%, or 5.7% excluding the impact of currency, compared to the prior year to $1.1 billion led by a strong rebound in the demand for cough/cold products. Fiscal year 2021 net sales increased 1.2%, or down 0.3% excluding the impact of currency, to $4.1 billion, including a negative impact of 1.7 percentage points from lower net sales of cough/cold products worldwide during the year. Fourth quarter GAAP ("reported") diluted earnings per share ("EPS") was $0.24, compared to a net loss per diluted shar
- PERRIGO TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS ON MARCH 1, 2022DUBLIN, Feb. 15, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and fiscal year 2021 financial results on Tuesday, March 1, 2022. The Company will also host a conference call beginning at 8:30 A.M. (EST). The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-317-6003, International 412-317-6061, and reference ID # 3221228. A taped replay of the call will be avai
- Perrigo Reports Third Quarter 2021 Financial Results From Continuing OperationsDUBLIN, Nov. 10, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO, TASE))) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced financial results for the third quarter of fiscal year 2021 ended October 2, 2021. All comparisons are against the prior year fiscal third quarter, unless otherwise noted. President and CEO, Murray S. Kessler commented, "Major initiatives were completed in the third quarter that will secure Perrigo a bright future. The RX generic prescription business divestiture was completed, the acquisition of the hig
- Perrigo To Release Third Quarter 2021 Financial Results On November 10, 2021DUBLIN, Oct. 27, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its third quarter 2021 financial results on Wednesday, November 10, 2021. The Company will also host a conference call beginning at 8:30 A.M. (EST). The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-317-6003, International 412-317-6061, and reference ID # 6950324. A taped replay of the call will be available begin
- Perrigo to Acquire Leading Consumer Self-Care Company, HRA PharmaDUBLIN, Sept. 8, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) ("Perrigo" or the "Company") today announced that it has signed a binding offer to acquire Héra SAS ("HRA" or "HRA Pharma"), a leading global consumer self-care company, from funds affiliated with private equity firm Astorg and Goldman Sachs Asset Management. The transaction is valued at €1.8 billion, or approximately $2.1 billion in cash. HRA is one of the fastest growing over-the-counter ("OTC") companies globally, with three category-leading self-care brands in blister care (Compeed®), women's health (ellaOne®) and scar care (Mederma®). This scale acquisition would complete Perrigo's transformation to a global le